Tramadol Abuse Among Patients Attending An Addiction Clinic in North-Eastern Nigeria: Outcome of a Four Year Retrospective Study
Advances in Psychology and Neuroscience
Volume 2, Issue 2-1, March 2017, Pages: 31-37
Received: Sep. 28, 2016; Accepted: Sep. 30, 2016; Published: Feb. 14, 2017
Views 3092      Downloads 152
Ibrahim A. W., Department of Mental Health, University of Maiduguri, Maiduguri, Nigeria; Department of Mental Health, Federal Neuropsychiatric Hospital, Maiduguri, Nigeria
Yerima M. M., College of Medical Sciences, Gombe State University, Gombe, Nigeria
Pindar S. K., Department of Mental Health, University of Maiduguri, Maiduguri, Nigeria
Onyencho V. C., Department of Clinical Psychology, Federal Neuropsychiatric Hospital, Maiduguri, Nigeria
Ahmed H. K., Department of Mental Health, Federal Neuropsychiatric Hospital, Maiduguri, Nigeria
Machina B. K., Department of Mental Health, Federal Neuropsychiatric Hospital, Maiduguri, Nigeria
Shehu S., Department of Psychiatry, Bayero University Kano, Kano, Nigeria
Rabbebe I. B., Department of Mental Health, Federal Neuropsychiatric Hospital, Maiduguri, Nigeria
Wakil M. A., Department of Mental Health, University of Maiduguri, Maiduguri, Nigeria
Article Tools
Follow on us
The 21st century Nigeria has witnessed changing trends in the patterns of psychoactive substance use with Tramadol HCl emerging as a candidate drug in the North-eastern region of the country. This study assessed the prevalence, patterns and the reasons behind the sustained use of Tramadol in a sub-population of drug users. This is a retrospective cross-sectional study in which socio-demographic, clinical and drug-related data were extracted from the clinical records of 237 drug users attending the addiction clinic of Federal Neuropsychiatric Hospital, Maiduguri, North-eastern Nigeria. The prevalence of Tramadol abuse was 54.4% [n=129] and 78 [60.5%, 95% C.I. = 54.1 - 65.7] met the ICD-10 diagnostic criteria for Tramadol dependence. Over 93% of Tramadol users were males and 87 [67.4%, 95% C.I. = 59.9 - 73.4] were in the 18 to 37 years age bracket. Over 67% used Tramadol in combination with other psychoactive substances while 65.1% [95% C.I. = 50.7 - 81.4] used multiple daily doses. Over 91% of the subjects obtained the drug without prescriptions and 12.4% [95% C.I. = 7.5 - 16.8] were first initiated to the drugs by prescriptions from health professionals. The commonest primary reasons for continuous usage were; to relieve tiredness [28.7%, 95% C.I.= 25.4 - 31.2] and to prolong the time of sexual intercourse [22.5%, 95% C.I. = 20.1 - 24.7]. Considering the addictive potentials of Tramadol, there is the need for; psychoeducational programmes for adolescents and young adults, rational prescriptions by clinicians and enhancing the operational capacities of regulatory agencies.
Tramadol, Abuse, North-Eastern Nigeria
To cite this article
Ibrahim A. W., Yerima M. M., Pindar S. K., Onyencho V. C., Ahmed H. K., Machina B. K., Shehu S., Rabbebe I. B., Wakil M. A., Tramadol Abuse Among Patients Attending An Addiction Clinic in North-Eastern Nigeria: Outcome of a Four Year Retrospective Study, Advances in Psychology and Neuroscience. Special Issue: Substance Abuse: Perspectives, Trends, Issues and the Way Forward. Vol. 2, No. 2-1, 2017, pp. 31-37. doi: 10.11648/j.apn.s.2017020201.16
Copyright © 2017 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License ( which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Gureje O, Degenhardt L, Olley B, Uwakwe R, Udofia, O, Wakil A, et al. (2007). A Descriptive Epidemiology of Substance Use and Substance Use Disorders in Nigeria During the Early 21st Century. Drug and Alcohol Dependence, 91: 1-9.
Copello A, Crome I, Smith GD, Egger M, Hickman M, Judd A, Macleod J, et al. (2002). The Psychosocial Consequences of Drug Misuse: A Systematic Review of Longitudinal Studies. Research Report submitted to the Department of Health, United Kingdom.
Moss HB, Bonicatto S, Kirisci L, Girardelli AM, Murrelle L. (1998). Substance abuse and Associated Psychosocial Problems Among Argentina Adolescents: Sex Heterogeneity and Familial Transmission. Drug Alcohol Depend, 52(3): 221-30.
French MT, Martin RF. (1996). The Costs of Drug Abuse Consequences: A Summary of Research Findings. J Subst Abuse Treat, 13(6): 453-66.
Burke TR. (1988). The Economic Impact of Alcohol Abuse and Alcoholism. Public Health Reports, 103(6): 564-568.
Chiang W, Goldfrank L. (1990). The Medical Complications of Drug Abuse. Med J Aust, 152(2): 83-88.
Asuni T (1978) The Drug Abuse Scene In Nigeria, In: Petersen RC (Ed.) The International Challenge Of Drug Abuse, Pp. 15 - 25 Maryland, National Institute On Drug Abuse.
Adamson TA, Ogunlesi AO, Morakinyo O, Akinhami AO, Onifade PO, Erinosho O, et al. (2015). Descriptive National Survey of Substance Use in Nigeria. J Addict Res Ther., 6; 234. doi:10.4172/2155-6105.1000234
Abasiubong F, Udobang JA, Idung AU, Udoh SB, Jombo HE. (2014). Pattern of Psychoactive Substance Useinthe Northern Region of Nigeria. African Journal of Drug and Alcohol Studies, 13(2):107-115.
Abasiubong F, Udobang JA, Idung AU, Udoh SB, Jombo HE. (2014). A Comparative Study of Pattern of Substance Use in Two Nigerian Cities Located in the Southern and Northern Nigeria. African Research Review, 8(2): 52-67.
Aliyu D, Adeleke IT, Anyebe EE, Omoniyi SO, Ibrahim LY.(2016). Occurrence, Patterns and Effects of Nonconventional Use of Substances among Youth in North-Central, Nigeria. World Journal of Preventive Medicine, 4(1): 12-19.
Pela AO. (1989). Recent Trends in Drug Use and Abuse in Nigeria. United Nations Office on Drugs and Crimes (UNODC)-Bulletin on Narcotics, 1:009.
Minami K, Uezono Y, Ueta Y.(2007). Pharmacological Aspects of the Effects of Tramadol on G-Protein Coupled Receptors. J Pharmacol Sci.,103(3):253–60.
Essential Medicines List 5th Revision (2010). A Publication of the Federal Ministry of Health (FMOH), Abuja, Nigeria.
Ehikhamenor EE, Aghahowa SE, Azodo CC. (2012). Retrospective Evaluation of Analgesics Prescribing Pattern in a Tertiary Hospital in Nigeria. Journal of Medicine and Biomedical Research, 11(1): 71-77.
Abdel-Hamid IA, Anderson KE, Waldinger MD, Anis TH. (2016). Tramadol and Sexual Function. Sexual Medicine Reviews, 4(3): 235-246.
Martyn-St James M, Cooper M, Kaltenthaler E, Dickinson K, Cantrell A, Wylie K, et al. (2015). Tramadol for Premature Ejaculation: A Systematic Review and Meta-analysis. BMC Urology, 15:6.
Nabil RM, El-Hamrawy LG, Shalaby AS, El-Bahy MS, AbdAllah MM. (2015). An Epidemiological Study of Tramadol HCl Dependence in an Outpatient Addiction Clinic at Heliopolis Psychiatric Hospital. Menoufia Medical Journal, 28(2): 591-596.
Jick H, Derby LE, Vasilakis C, Fife D. (1998). The Risk of Seizure Associated with Tramadol. Pharmacotherapy, 18: 607-611.
Boostani R, Derakhshan S. (2012). Tramadol Induced Seizure: A 3-year Study. Caspian J Intern Med, 3(3): 484-487.
Barsotti CE, Mycyk MB, Reyes J. (2003). Withdrawal syndrome from Tramadol hydrochloride. The American Journal of Emergency Medicine, 21(1): 87-94.
Senay EC, Adams EH, Geller A, Inciardi JA, Munoz A, Schnoll SH, Woody GE, Cicero TJ. (2003). Physical Dependence on Ultram (Tramadol HCl): Both Opioid-like and Atypical Withdrawal Symptoms Occur. Drug Alcohol Depend, 69(3): 233-241.
Lanier RK, Lofwall MR, Mintzer MZ, Bigelow GE, Strain EC. (2010). Physical Dependence Potential of Daily Tramadol Dosing in Humans. Psychopharmacology, 211(4): 457-466.
Rajabizadeh G, Kheradmand A, Nasirian M. (2009). Psychosis Following Tramadol Withdrawal. Addict and Health, 1(1): 58-61.
El-Hadidy MA, Nabil-Helaly AM. (2015). Medical and Psychiatric Effects of Long-term Dependence on High Dose Tramadol. Substance Use and Misuse, 50(5): 582-589.
Bassiony MM, SalahElDeen GM, Yousef M, Raya Y, Abdel-Ghani MM, El-Gohari H, Atwa SA. (2015). Adolescent Tramadol Use and Abuse in Egypt. The American Journal of Drug and Alcohol Abuse, 41(3): 2-6.
Zabihi E, Hoseinzaadeh A, Emami M, Mardani M, Mahmoud B, Akbar MA. (2011). Potential for Tramadol Abuse by Patients Visiting Pharmacies in Northern Iran. Substance Abuse: Research and Treatment, 5: 11-15.
Archives of the Medical Records Department, Federal Neuropsychiatric Hospital, Maiduguri. Accessed on the 23rd July, 2016.
Borofka A, Olatawura MO. (1976). Community Psychiatry in Nigeria: The Current Status. Int J Soc Psychiatr, 23: 1154-8.
Bashirian S, Barati M, Fathi Y. (2014). Prevalence and Factors Associated With Tramadol Abuse Among College Students in West of Iran: An Application of the Theory of Planned Behaviour. Avicenna J NeuroPsychPhysio.,1(1): e20314.
Reed MD, Rountree PW. (1997). Peer Pressure and Adolescent Substance Use. Journal of Quantitative Criminology, 13(2): 143-180.
Simons-Morton B, Farhat T. (2010). Recent Findings on Peer Group Influences on Adolescent Substance Use. J Prim Prev., 31(4): 191-208.
Jordan-Jinez ML, Souza JRM, Pillon SC. (2009). Drug Use and Risk Factors Among Secondary Students. Rev Latino-am Enfermagem, 17(2): 246-252.
Gopiram P, Kishore MT. (2014). Psychosocial Attributes of Substance Abuse Among Adolescents and Young Adults: A Comparative Study of Users and Non-users. Indian J Psychol Med., 36(1): 58-61.
Osman T, Catherine C, Abdulmooneim A, Mohammed H, Abdalla F, Ahmed A, et al. (2016). Epidemiology of Substance Use Among University Students in Sudan. Journal of Addiction, Article ID 2476164.
Onyencho VC, Ibrahim AW, Pindar SK, Makput D, Mshelia AA, Rabbebe IB, et al. (2016). Personality Traits of In-patients with Substance Use Disorders in a Mental Health Facility in Nigeria. Journal of Neuroscience and Behavioral Health, 8(1): 1-8.
Khosrojerdi H, Talesh GA, Danaei GH, Saremi SS, Adab A, Afshari R. (2015). Tramadol Half-life is Dose Dependent in Overdose. DARU Journal of Pharmaceutical Sciences, 23: 22.DOI10.1186/s40199-015-0104-y.
Liu ZM, Zhou WH, Lian Z, Mu Y, Ren ZH, Cao JQ, Cai ZJ. (1999). Drug Abuse and Dependence Potential of Tramadol. Acta Pharmacologica Sinuca, 20(1): 52-54.
Science Publishing Group
1 Rockefeller Plaza,
10th and 11th Floors,
New York, NY 10020
Tel: (001)347-983-5186